CHAD Therapeutics, Inc. has announced that it has been named the 2006 Frost & Sullivan Product Line Strategy Leadership Award winner for its excellence in the U.S. oxygen therapy devices market.
“We are proud to receive this prestigious award, which reflects our total team effort to quality and service,” said Earl Yager, president and CEO. “Our product strategy recognizes that home care providers are seeking ways to reduce monthly operating costs as a primary strategy to deal with changes in the competitive landscape and reduced Medicare reimbursement. We are dedicated to addressing these requirements, while offering the industry’s widest range of advanced oxygen therapy products to improve the quality of life for patients.”
Sheila Ewing, Frost & Sullivan research analyst, said, “CHAD Therapeutics has responded to the changes in the U.S. oxygen therapy devices market with complementary new products that position the company for growth. CHAD Therapeutics’ proprietary devices, including its TOTAL O2®home oxygen filling system, LOTUS electronic oxygen conserver and SAGE Oxygen Therapeutic Device, employ some of the most revolutionary advances in technology in this industry to improve patient care and provide cost-effective treatment options for home care providers.”
The Frost & Sullivan Award for Oxygen Therapy Product Line Strategy Leadership is presented each year to a company that has demonstrated the most insight into customer needs and product demands. The recipient company has optimized its product line by leveraging products with the various price, performance and feature points required by the market. To select the Award recipient, the analyst team tracks all end-user requirements and market dynamics with the industry. This process includes interviews with suppliers, end-users and industry experts. The product lines are compared with customer base demands, and the top-ranking supplier is then presented the award.
Visit www.chadtherapeutics.com.
